The head of US pharmaceutical conglomerate Pfizer defended plans to acquire UK rival AstraZeneca as Pfizer chief executive Ian Read spoke to a panel of British lawmakers about the deal.
”We don’t see any substantial antitrust issues on this deal anywhere in the world,” Read said.
The merger would mark the largest acquisition of a UK company by a foreign firm and create a pharmaceutical behemoth. No merger deal has been officially made, but Pfizer has offered $106 billion to acquire the UK firm – a figure AstraZeneca said was too low.
Experts are eyeing the proposed acquisition carefully and say if a deal is ever reached it would likely face intense scrutiny from competition regulators. Earlier reports said UK authorities would likely face a battle with the European Commission to review such a deal.
Full content: Business Report
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI